BioVendor Group has recently acquired from SqLab Labor GmbH the remaining minority stake in ViennaLab Diagnostics GmbH. ViennaLab is now a 100% member of the BioVendor Group.
BioVendor Group, an international diagnostics holding with headquarters in Brno, Czech Republic, currently employs over 450 staff across 11 companies in 9 countries. For BioVendor Group this acquisition represents another important step towards the vision of becoming a globally recognised, innovative, integrated IVD company, supplying primarily clinical customers with diagnostic solutions based on immunoassays and molecular diagnostics.
The acquisition also brings about a change in the leadership of ViennaLab Diagnostics: Martin Zeppetzauer has been appointed as the new Chief Executive Officer (CEO) as of September 1st, and will lead all commercial activities towards further growing the company. Martin previously held business development positions in the pharmaceutical industry focusing on clinical research and development.
In a statement Martin Zeppetzauer says “I am delighted to be appointed to this position and look forward to joining an outstanding team that has introduced an extensive portfolio of high-quality in vitro diagnostic products to the market. While 2020 has brought unprecedented challenges to the world we would like to assure our customers that ViennaLab Diagnostics will continue to be a reliable provider of high-quality and easy-to-use diagnostic solutions.
“I very much look forward to continuing and where possible intensifying the established collaborations with our valued customers and partners.”
Christian Oberkanins will take on the role of Chief Technology Officer (CTO) and will be responsible for the technological and scientific advancement of ViennaLab Diagnostics.
For our customers, the established procedures and contacts in terms of orders, deliveries and support will remain unchanged.
Together with the established micro RNA (miRNA) R&D team in Brno, ViennaLab Diagnostics shall form the basis of an expanding BioVendor Group molecular diagnostics (MDx) division. For our customers this will mean access to new assays and technology such as NGS kits for various indications.
Questions or Comments can be sent to: [email protected]